Veryan has received CE mark approval for the BioMimics 3D stent, its novel platform technology designed for treatment of the superficial femoral and proximal popliteal (femoropopliteal) arteries.
According to a company release, the BioMimics 3D stent features a unique three-dimensional design that mimics the natural helical geometry of the human vascular system. The intention of the design is to improve characteristics of blood flow in the stented segment that may confer a vasoprotective effect and enhance biomechanical performance, with the prospect that kinking, deformation and consequential vessel trauma during leg flexion may be reduced, compared to a standard nitinol stent.
The CE mark approval was based on meeting the primary endpoints of the MIMICS study, a prospective randomised controlled trial comparing the safety and efficacy of the BioMimics 3D stent with a standard nitinol stent in patients with peripheral arterial disease undergoing femoropopliteal artery intervention. The BioMimics 3D stent demonstrated an excellent safety profile and promising clinical performance at both six and 12 month time points. Follow-up assessments of patients in the MIMICS study will continue for two years.
Interim data were presented at the VIVA meeting (Las Vegas, USA, 9–12 October). At six months, all 50 patients that received treatment with the BioMimics 3D stent were free from clinically-driven target lesion revascularisation (CD TLR), and there were no deaths or amputations. Of the 36 patients treated with BioMimics 3D stents who had reached the 12-month follow-up time point, 33(91.7%) remained free from CD TLR, compared with 18 of the 21 (85.7%) from the control group who reached the same follow-up time point. The independent core lab has not detected any stent fractures to date in either treatment group.
“Besides reducing the risk of stent fracture, the unique BioMimics 3D stent architecture has been shown in preclinical animal studies to transform a laminar flow into a swirling flow, a phenomenon known to increase wall shear stress, which may mitigate the development of neointimal hyperproliferation,” said MIMICS principal investigator, Thomas Zeller, University Heart Centre, Freiburg-Bad Krozingen, Germany. “The six–month results of the trial have proven the safety of the new stent design, and we are eagerly awaiting the twelve-month patency results where we expect at least a positive performance signal.”